文献速递临床血液与体液临床生化临床免疫

COVID-19重症与死亡相关血液、生化及免疫标志物异常:一项荟萃分析

Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis.
PubMed 文献 · Clin Chem Lab Med · 2020-01-01

该荟萃分析纳入21项研究共3377例COVID-19患者,评估33项实验室参数在重症与非重症、死亡与存活患者间的差异。重症及死亡患者白细胞计数升高,淋巴细胞和血小板计数降低,炎症、心肌、肌肉、肝肾功能及凝血标志物显著升高;IL-6、IL-10和血清铁蛋白对重症鉴别力强。建议对住院呼吸窘迫患者密切监测WBC、淋巴细胞、血小板、IL-6和血清铁蛋白。

要点

  • 重症和死亡COVID-19患者白细胞计数升高,淋巴细胞和血小板计数降低。
  • 炎症、心肌、肌肉、肝肾功能及凝血标志物在重症和死亡患者中显著升高。
  • IL-6、IL-10和血清铁蛋白对重症COVID-19有较强鉴别力。

核心结论

  • 多项生物标志物可能有助于预测COVID-19重症和死亡的风险分层。
  • 对住院呼吸窘迫患者,建议密切监测WBC计数、淋巴细胞计数、血小板计数、IL-6和血清铁蛋白作为进展至危重症的标志物。

研究设计与样本

  • 电子检索Medline(PubMed)、Scopus、Web of Science和中国知网(CNKI)筛选报告COVID-19实验室异常的研究。
  • 共纳入21项研究、3377例患者、33项实验室参数;18项研究(n=2984)比较重症与非重症,3项研究(n=393)比较死亡与存活并单独分析。
  • 采用荟萃分析合并数据,以加权均数差(WMD)及95%置信区间(95%CI)估计各实验室参数的差异。

主要发现

  • 重症和死亡患者较非重症和存活者白细胞计数显著升高,淋巴细胞和血小板计数显著降低。
  • 炎症、心肌和肌肉损伤、肝肾功能及凝血指标在重症和死亡COVID-19患者中均显著升高。
  • IL-6、IL-10和血清铁蛋白对重症疾病有较强鉴别力。

临床怎么用

  • 对住院呼吸窘迫的COVID-19患者,密切监测WBC计数、淋巴细胞计数、血小板计数、IL-6和血清铁蛋白,作为潜在进展至危重症的标记。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background As coronavirus disease 2019 (COVID-19) pandemic rages on, there is urgent need for identification of clinical and laboratory predictors for progression towards severe and fatal forms of this illness. In this study we aimed to evaluate the discriminative ability of hematologic, biochemical and immunologic biomarkers in patients with and without the severe or fatal forms of COVID-19. Methods An electronic search in Medline (PubMed interface), Scopus, Web of Science and China National Knowledge Infrastructure (CNKI) was performed, to identify studies reporting on laboratory abnormalities in patients with COVID-19. Studies were divided into two separate cohorts for analysis: severity (severe vs. non-severe and mortality, i.e. non-survivors vs. survivors). Data was pooled into a meta-analysis to estimate weighted mean difference (WMD) with 95% confidence interval (95% CI) for each laboratory parameter. Results A total number of 21 studies was included, totaling 3377 patients and 33 laboratory parameters. While 18 studies (n = 2984) compared laboratory findings between patients with severe and non-severe COVID-19, the other three (n = 393) compared survivors and non-survivors of the disease and were thus analyzed separately. Patients with severe and fatal disease had significantly increased white blood cell (WBC) count, and decreased lymphocyte and platelet counts compared to non-severe disease and survivors. Biomarkers of inflammation, cardiac and muscle injury, liver and kidney function and coagulation measures were also significantly elevated in patients with both severe and fatal COVID-19. Interleukins 6 (IL-6) and 10 (IL-10) and serum ferritin were strong discriminators for severe disease. Conclusions Several biomarkers which may potentially aid in risk stratification models for predicting severe and fatal COVID-19 were identified. In hospitalized patients with respiratory distress, we recommend clinicians closely monitor WBC count, lymphocyte count, platelet count, IL-6 and serum ferritin as markers for potential progression to critical illness.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis. Clin Chem Lab Med. 2020. PMID: 32286245. doi:10.1515/cclm-2020-0369

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。